大剂量沐舒坦治疗重度急性呼吸窘迫综合征的疗效观察

The Therapeutic Effect of Large Dose Ambroxol in Treatment of Severe ARDS

目的:研究大剂量沐舒坦对重度急性呼吸窘迫综合征(ARDS)患者的疗效。方法:根据2012ARDS柏林标准选择重度ARDS患者40例,随机分成对照组(20例)和试验组(20例)。两组患者常规治疗的同时,对照组每天给予生理盐水20 ml静脉推注,每6小时一次,试验组每天给予生理盐水20 ml加沐舒坦150 mg静脉推注,每6小时一次,连续应用7 d。比较两组患者在治疗7 d前后APACHEⅡ评分、肺顺应性、氧合指数及ICU停留时间的差异。结果:与对照组相比,试验组患者7 d后的APACHEⅡ评分、氧合指数、肺顺应性有明显改善,ICU停留时间缩短,两组差异有统计学意义(P<0.05)。结论:大剂量沐舒坦可以改善重度ARDS患者肺顺应性,提高氧合指数,缩短ICU住院时间。

Objective To study the effect of high dose Ambroxol on patients with the severe acute respiratory distress syndrome（ARDS）. Method According to 2012 Berlin diagnostic criteria of ARDS,40 cases patients with severe ARDS were randomly divided into control group （20 cases） and test group （20 cases）. Beside the two groups of patients were under the conventional treatment,control group received 0. 9% NaC1 20 ml Q 6 h for 7 d and the test group was given 0. 9% NaC1 20 ml and Ambroxol 150 nag Q 6 h for 7d. Compared between the two groups with APACHE 11 score,lung compliance, oxygenation index and the ICU stay time before and after the treatment. Results Relative to the control group, APACHE ]I score, the oxygen index and pulmonary compliance of the test group had improved significantly after 7 d, the ICU stay time was shorten, the difference was statistically significant （P 〈 0. 05 ）. Condusion The application of large dose ambroxol can improve severe ARDS patients with pulmonary compliance ,improve oxygenation, shorten the ICU stay time.